Evidence map›Paper›PMID 35974050›Full record

ArticleScientific reports2022

Personalized survival probabilities for SARS-CoV-2 positive patients by explainable machine learning.

Adrian G Zucco, Rudi Agius, Rebecka Svanberg, Kasper S Moestrup, Ramtin Z Marandi, Cameron Ross MacPherson, Jens Lundgren, Sisse R Ostrowski, Carsten U Niemann

Abstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Adrian G ZuccoPERSIMUNE Center of Excellence, Rigshospitalet, Copenhagen, Denmark. adrian.gabriel.zucco@regionh.dk.
Rudi AgiusDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark.
Rebecka SvanbergDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark.
Kasper S MoestrupPERSIMUNE Center of Excellence, Rigshospitalet, Copenhagen, Denmark.
Ramtin Z MarandiPERSIMUNE Center of Excellence, Rigshospitalet, Copenhagen, Denmark.
Cameron Ross MacPhersonPERSIMUNE Center of Excellence, Rigshospitalet, Copenhagen, Denmark.
Jens LundgrenPERSIMUNE Center of Excellence, Rigshospitalet, Copenhagen, Denmark.
Sisse R OstrowskiDepartment of Clinical Immunology, Rigshospitalet, Copenhagen, Denmark. Sisse.Rye.Ostrowski@regionh.dk.
Carsten U NiemannDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark. Carsten.Utoft.Niemann@regionh.dk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interpretable risk assessment of SARS-CoV-2 positive patients can aid clinicians to implement precision medicine. Here we trained a machine learning model to predict mortality within 12 weeks of a first positive SARS-CoV-2 test. By leveraging data on 33,938 confirmed SARS-CoV-2 cases in eastern Denmark, we considered 2723 variables extracted from electronic health records (EHR) including demographics, diagnoses, medications, laboratory test results and vital parameters. A discrete-time framework for survival modelling enabled us to predict personalized survival curves and explain individual risk factors. Performance on the test set was measured with a weighted concordance index of 0.95 and an area under the curve for precision-recall of 0.71. Age, sex, number of medications, previous hospitalizations and lymphocyte counts were identified as top mortality risk factors. Our explainable survival model developed on EHR data also revealed temporal dynamics of the 22 selected risk factors. Upon further validation, this model may allow direct reporting of personalized survival probabilities in routine care.

Indexed as

COVID-19SARS-CoV-2HumansMachine LearningRetrospective StudiesRisk FactorsROC Curve

Identifiers

PMID35974050
PMCPMC9380679

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.